{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-003563","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2025-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.494590+00:00","generated_at":"2026-05-26T22:46:56.549081+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aytu BioPharma reports Q2 net income $0.8M; Pediatric revenue up 86% sequentially","bullets":["Net revenue $16.2M, down 13% YoY; ADHD revenue fell 17% to $13.8M, Pediatric rose 12% to $2.4M.","Net income $0.8M ($0.13 basic EPS) vs net loss $0.2M in Q2FY24; adjusted EBITDA $1.3M vs $5.5M.","Sequential prescription growth for both ADHD and Pediatric portfolios, first since Q2FY23.","Cash $20.4M at Dec 31, 2024, flat vs Sep 30; cost savings initiatives to cut at least $2M annually.","Gross margin 66% vs 78% a year ago due to higher-cost ADHD inventory from manufacturing transition."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-003563","json":"https://secwatch.observer/filing/0001437749-25-003563.json","markdown":"https://secwatch.observer/filing/0001437749-25-003563.md","text":"https://secwatch.observer/filing/0001437749-25-003563.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925003563/0001437749-25-003563-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925003563/aytu20241121_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:46:56.549081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}